Astellas PharmaALPMF 73 ROC (Joel Greenblatt) % is 36.35% as of Mar. 2026, which is 47% below its 10-year median of 68.12. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 977 Drug Manufacturers companies, Astellas Pharma ranks better than 89.87% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Astellas Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 36.35%.
The historical rank and industry rank for Astellas Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
ALPMF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.82 Med: 68.12 Max: 104.42
Current: 71.83
During the past 13 years, Astellas Pharma's highest ROC (Joel Greenblatt) % was 104.42%. The lowest was 11.82%. And the median was 68.12%.
ALPMF's ROC (Joel Greenblatt) % is ranked better than 89.87% of 977
companies
in the Drug Manufacturers industry
Industry Median: 11.37
vs ALPMF: 71.83
Astellas Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -12.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Astellas Pharma ROC (Joel Greenblatt) % Related Terms
Astellas Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 36.35% mean?
Astellas Pharma (ALPMF) has a ROC (Joel Greenblatt) % of 36.35% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Astellas Pharma and its competitors. This is 47% below median its historical median of 68.12. Over the past decade, Astellas Pharma's ROC (Joel Greenblatt) % has ranged from 11.82 to 104.42. According to the industry distribution chart, Astellas Pharma ranks #99 out of 977 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Astellas Pharma's ROC (Joel Greenblatt) % too high?
Astellas Pharma's current ROC (Joel Greenblatt) % of 36.35% is 47% below median its 10-year median of 68.12. Over the past 10 years, this metric has ranged from a low of 11.82 to a high of 104.42. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.37. Astellas Pharma's value of 36.35% is 219.7% above this industry median. Based on the distribution chart, Astellas Pharma ranks #99 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #99 out of 977 companies for ROC (Joel Greenblatt) %. This places Astellas Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.37. Astellas Pharma's value of 36.35% is 219.7% above this benchmark. Historically, Astellas Pharma's own ROC (Joel Greenblatt) % has ranged from 11.82 to 104.42 over the past decade. While the company's 10-year median is 68.12 vs. the industry median of 11.37, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.37, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current ROC (Joel Greenblatt) % of 36.35% is 219.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current ROC (Joel Greenblatt) % is 36.35%, which is 47% below median its own 10-year median of 68.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.60, compared to a current price of $14.15 — trading 3.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 36.35%, which is 47% below median its 10-year median of 68.12 and 219.7% above the Drug Manufacturers industry median of 11.37. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current ROC (Joel Greenblatt) % is 36.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $14.15 is trading 3.1% below its estimated GF Value™ of $14.60.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
ROC (Joel Greenblatt) %: 36.35% (47% below median its 10-year median of 68.12)
GF Value™: $14.60 vs. price of $14.15 (3.1% below fair value)
Industry Position: 219.7% above the Drug Manufacturers median (#99 of 977)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
